Targeted CHO cell engineering approaches can reduce HCP‐related enzymatic degradation and improve mAb product quality

Host cell proteins (HCP) that co‐purify with biologics produced in Chinese hamster ovary cells have been shown to impact product quality through proteolytic degradation of recombinant proteins, leading to potential product losses. Several problematic HCPs can remain in the final product even after extensive purification. Each recombinant cell line has a unique HCP profile that can be determined by numerous upstream and downstream factors, including clonal variation and the protein sequence of the expressed therapeutic molecule. Here, we worked with recombinant cell lines with high levels of copurifying HCPs, and showed that in those cell lines even modest downregulation (≤50%) of the difficult to remove HCP Cathepsin D, through stable short hairpin RNA interference or monoallelic deletion of the target gene using CRISPR‐Cas9, is sufficient to greatly reduce levels of co‐purifying HCP as measured by high throughput targeted LC‐MS. This reduction led to improved product quality by reducing fragmentation of the drug product in forced degradation studies to negligible levels. We also show the potential of cell engineering to target other undesired HCPs and relieve the burden on downstream purification. Host cell proteins (HCPs) removal is usually achieved through purification process, however, certain HCPs pose challenges. In this paper, targeted CHO cell engineering approaches, such as shRNA and CRISPR‐Cas 9, were used to reduce enzymatic degradation caused by Cathepsin D and improve mAb product quality.